Friday, 29 March 2024


PAREXEL, Eli Lilly to develop China’s Clinical Research workforce

06 December 2018 | News

The program will bring high-value training opportunities to China’s clinical trial sites and investigators.

Image credit- pauwelsconsulting.com

Image credit- pauwelsconsulting.com

PAREXEL, a leading innovator of global biopharmaceutical services, has announced a new collaboration with Eli Lilly and Company to launch a clinical research learning and development program in China. The program will bring high-value training opportunities to China’s clinical trial sites and investigators, enhancing the execution of local clinical trials and driving innovation in China’s biopharmaceutical industry.

To encourage innovation in drug development, the Chinese government recently released a series of new policies for clinical research, resulting in a sharp increase in the number of clinical trials in China. According to China’s clinical trial registration platform, 1,258 drug clinical trials were registered and publicized for the first time in China in 2017, an increase of 62.66 percent compared to 2016. This increase in clinical research demands has put a strain on the clinical research capacity and resources in China. A recent report indicates that the total number of class 1.1 chemical drugs and class 1 biologic drugs approved for clinical trials from January to October 2017 was three times that of 2014. Still, the number of GCP-qualified clinical trial sites did not significantly increase between 2014 and 2016.

PAREXEL and Lilly’s collaboration is based on a shared vision to address this unmet need and promote globalization and innovation of the market’s drug development. The joint program will use curriculum developed by PAREXEL Academy for clinical trial investigators, and issue certifications to professionals who complete the training. Designed by clinical research practitioners, the curriculum combines the latest policies, regulations and clinical research technologies. It also uses behavior-oriented curriculum design, real-world cases, as well as advanced knowledge and industry trends, to provide world-class expertise and practical experience for clinical research investigators. The curriculum has been reviewed and certified by TransCelerate BioPharma, Inc., an international non-profit organization focused on biopharmaceutical research and development.

Sign up for the editor pick and get articles like this delivered right to your inbox.

Editors Pick
+Country Code-Phone Number(xxx-xxxxxxx)


Comments

× Your session has been expired. Please click here to Sign-in or Sign-up
   New User? Create Account